Harsh Shah

Has grant

Clinical Assistant Professor

Huntsman Cancer Institute

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Anti-PD-1 and anti-CSF1-R blockade in patients with relapsed/refractory classical Hodgkin Lymphoma

Open Date: 2022-04-01

Close Date: 2024-10-31

Articles (12)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (3)

Julio Chavez

Associate Professor

Moffitt Cancer Center

UNITED STATES

View details

Randa Tao

University of Utah School of Medicine

UNITED STATES

View details

Francine Foss

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Harsh Shah

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (12)

T‐cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments

Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy

Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for early‐stage classical Hodgkin Lymphoma: Updated results from an ongoing phase 2 study (SGN35‐027 Part C)

Efficacy of brentuximab consolidation by metabolic response in an international real‐world cohort of classic Hodgkin lymphoma at high risk for progression after ASCT

OUTCOMES OF AUTOLOGOUS TRANSPLANT, ALLOGENEIC TRANSPLANT, AND CAR T CELL THERAPY IN TP53 ALTERED MANTLE CELL LYMPHOMA: A MULTI‐INSTITUTION RETROSPECTIVE ANALYSIS

Overall survival in classic Hodgkin lymphoma pts who progress after autologous stem cell transplant in the era of novel agents

PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (<i>R/R</i> DLBCL)

Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of realworld outcomes

A comprehensive SEER registry analysis of elderly patients with classical Hodgkin lymphoma based on treatment era and race

Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era

Collaborators (3)

Julio Chavez

Randa Tao

Francine Foss

Make your next move.